(COLL) Collegium Pharmaceutical - Ratings and Ratios
Oxycodone, Hydrocodone, Opioid Painkillers, Abuse-Deterrent, Formulations
COLL EPS (Earnings per Share)
COLL Revenue
Description: COLL Collegium Pharmaceutical
Collegium Pharmaceutical Inc (NASDAQ:COLL) is a US-based pharmaceutical company. As a player in the pharmaceutical industry, the companys performance is influenced by factors such as R&D pipeline, product approvals, and market competition.
The companys market capitalization stands at approximately $1.185 billion, indicating a mid-cap status. The price-to-earnings (P/E) ratio is 35.50, suggesting that investors are willing to pay a premium for the companys earnings. However, the forward P/E ratio is significantly lower at 5.34, implying expected earnings growth. Return on Equity (RoE) is 15.60%, indicating a relatively strong return for shareholders.
Key economic drivers for Collegium Pharmaceutical include the demand for its pharmaceutical products, pricing and reimbursement policies, and the competitive landscape. Key Performance Indicators (KPIs) to watch include revenue growth, gross margin, R&D expenses as a percentage of revenue, and cash flow generation. The companys ability to develop and commercialize new products, as well as its manufacturing and supply chain efficiency, will be crucial in driving future performance.
Investors should also consider the companys valuation multiples, such as the P/E ratio, in the context of its peers and the broader industry. Additionally, the companys beta of 0.684 suggests relatively lower volatility compared to the overall market. As a trading analyst, it is essential to monitor the companys progress on its R&D pipeline, product approvals, and commercial execution to assess its potential for future growth.
COLL Stock Overview
| Market Cap in USD | 1,247m |
| Sub-Industry | Pharmaceuticals |
| IPO / Inception | 2015-05-07 |
COLL Stock Ratings
| Growth Rating | 49.2% |
| Fundamental | 71.3% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -15.0% |
| Analyst Rating | 4.20 of 5 |
COLL Dividends
Currently no dividends paidCOLL Growth Ratios
| Growth Correlation 3m | 85.4% |
| Growth Correlation 12m | -16.1% |
| Growth Correlation 5y | 72% |
| CAGR 5y | 29.55% |
| CAGR/Max DD 3y | 0.72 |
| CAGR/Mean DD 3y | 1.50 |
| Sharpe Ratio 12m | 0.37 |
| Alpha | -7.24 |
| Beta | 0.381 |
| Volatility | 33.83% |
| Current Volume | 412.9k |
| Average Volume 20d | 423.3k |
| Stop Loss | 36.1 (-3.3%) |
| Signal | -2.12 |
Piotroski VR‑10 (Strict, 0-10) 3.0
| Net Income (36.3m TTM) > 0 and > 6% of Revenue (6% = 42.4m TTM) |
| FCFTA 0.13 (>2.0%) and ΔFCFTA -13.49pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 11.97% (prev 8.41%; Δ 3.56pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.13 (>3.0%) and CFO 203.5m > Net Income 36.3m (YES >=105%, WARN >=100%) |
| Net Debt (711.8m) to EBITDA (346.7m) ratio: 2.05 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.18 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (39.1m) change vs 12m ago -3.24% (target <= -2.0% for YES) |
| Gross Margin 56.69% (prev 61.94%; Δ -5.26pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 53.44% (prev 54.74%; Δ -1.30pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 1.64 (EBITDA TTM 346.7m / Interest Expense TTM 82.3m) >= 6 (WARN >= 3) |
Altman Z'' 0.61
| (A) 0.05 = (Total Current Assets 549.2m - Total Current Liabilities 464.6m) / Total Assets 1.59b |
| (B) -0.09 = Retained Earnings (Balance) -149.6m / Total Assets 1.59b |
| (C) 0.10 = EBIT TTM 135.3m / Avg Total Assets 1.32b |
| (D) -0.11 = Book Value of Equity -149.2m / Total Liabilities 1.36b |
| Total Rating: 0.61 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 71.29
| 1. Piotroski 3.0pt = -2.0 |
| 2. FCF Yield 10.91% = 5.0 |
| 3. FCF Margin 28.54% = 7.14 |
| 4. Debt/Equity 3.55 = -1.53 |
| 5. Debt/Ebitda 2.38 = -0.73 |
| 6. ROIC - WACC 3.65% = 4.57 |
| 7. RoE 15.60% = 1.30 |
| 8. Rev. Trend 92.70% = 4.64 |
| 9. Rev. CAGR 15.33% = 1.92 |
| 10. EPS Trend 39.97% = 1.00 |
| 11. EPS CAGR 0.0% = 0.0 |
What is the price of COLL shares?
Over the past week, the price has changed by -1.14%, over one month by +0.43%, over three months by +25.61% and over the past year by +0.57%.
Is Collegium Pharmaceutical a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of COLL is around 40.35 USD . This means that COLL is currently overvalued and has a potential downside of 8.12%.
Is COLL a buy, sell or hold?
- Strong Buy: 2
- Buy: 2
- Hold: 1
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the COLL price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 44.6 | 19.5% |
| Analysts Target Price | 44.6 | 19.5% |
| ValueRay Target Price | 43.7 | 17% |
Last update: 2025-09-05 04:37
COLL Fundamental Data Overview
CCE Cash And Equivalents = 222.2m USD (Cash And Short Term Investments, last quarter)
P/E Trailing = 37.3491
P/E Forward = 5.5279
P/S = 1.764
P/B = 5.3682
Beta = 0.684
Revenue TTM = 707.0m USD
EBIT TTM = 135.3m USD
EBITDA TTM = 346.7m USD
Long Term Debt = 758.3m USD (from longTermDebt, last quarter)
Short Term Debt = 65.9m USD (from shortTermDebt, last quarter)
Debt = 824.3m USD (Calculated: Short Term 65.9m + Long Term 758.3m)
Net Debt = 711.8m USD (from netDebt column, last quarter)
Enterprise Value = 1.85b USD (1.25b + Debt 824.3m - CCE 222.2m)
Interest Coverage Ratio = 1.64 (Ebit TTM 135.3m / Interest Expense TTM 82.3m)
FCF Yield = 10.91% (FCF TTM 201.8m / Enterprise Value 1.85b)
FCF Margin = 28.54% (FCF TTM 201.8m / Revenue TTM 707.0m)
Net Margin = 5.13% (Net Income TTM 36.3m / Revenue TTM 707.0m)
Gross Margin = 56.69% ((Revenue TTM 707.0m - Cost of Revenue TTM 306.2m) / Revenue TTM)
Tobins Q-Ratio = -12.39 (set to none) (Enterprise Value 1.85b / Book Value Of Equity -149.2m)
Interest Expense / Debt = 2.48% (Interest Expense 20.5m / Debt 824.3m)
Taxrate = 29.80% (29.4m / 98.6m)
NOPAT = 95.0m (EBIT 135.3m * (1 - 29.80%))
Current Ratio = 1.18 (Total Current Assets 549.2m / Total Current Liabilities 464.6m)
Debt / Equity = 3.55 (Debt 824.3m / last Quarter total Stockholder Equity 232.2m)
Debt / EBITDA = 2.38 (Net Debt 711.8m / EBITDA 346.7m)
Debt / FCF = 4.08 (Debt 824.3m / FCF TTM 201.8m)
Total Stockholder Equity = 232.4m (last 4 quarters mean)
RoA = 2.28% (Net Income 36.3m, Total Assets 1.59b )
RoE = 15.60% (Net Income TTM 36.3m / Total Stockholder Equity 232.4m)
RoCE = 13.66% (Ebit 135.3m / (Equity 232.4m + L.T.Debt 758.3m))
RoIC = 8.81% (NOPAT 95.0m / Invested Capital 1.08b)
WACC = 5.16% (E(1.25b)/V(2.07b) * Re(7.42%)) + (D(824.3m)/V(2.07b) * Rd(2.48%) * (1-Tc(0.30)))
Shares Correlation 3-Years: -21.21 | Cagr: 1.12%
Discount Rate = 7.42% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
[DCF Debug] Terminal Value 80.79% ; FCFE base≈231.3m ; Y1≈272.4m ; Y5≈417.6m
Fair Price DCF = 227.3 (DCF Value 7.16b / Shares Outstanding 31.5m; 5y FCF grow 18.92% → 3.0% )
Revenue Correlation: 92.70 | Revenue CAGR: 15.33%
Rev Growth-of-Growth: 10.67
EPS Correlation: 39.97 | EPS CAGR: 0.0%
EPS Growth-of-Growth: -210.2
Additional Sources for COLL Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle